ການສຶກສາກໍລະນີໂຣກມະເຮັງປອດແລະການທົດລອງທາງຄລີນິກ

1. ການວິນິດໄສ ແລະ ການປິ່ນປົວພະຍາດມະເຮັງປອດຄັ້ງທຳອິດ

ຄົນເຈັບ Lu ໄດ້ຖືກກວດພົບວ່າເປັນໂຣກປອດ adenocarcinoma ແລະ lymph node metastasis ໃນວັນທີ 26 ສິງຫາ 2005. A lobectomy ຕ່ໍາຊ້າຍໄດ້ຖືກປະຕິບັດໃນວັນທີ 22 ກັນຍາ 2005. Carboplatin ລວມກັບ taxotere ຖືກນໍາໃຊ້ 4 ຄັ້ງຫຼັງຈາກການຜ່າຕັດ. ໃນເດືອນສິງຫາ 3, 2007, ເນື່ອງຈາກ pleural effusion, ການວິນິດໄສໄດ້ຖືກຢືນຢັນວ່າຈະເກີດຂຶ້ນຄືນໃຫມ່, ແລະນາງໄດ້ຮັບການປິ່ນປົວດ້ວຍ Tarceva (ບໍ່ຮູ້ຈັກຈໍານວນຂອງຮອບວຽນ). ໃນເດືອນມັງກອນ 8, 2008, ຄວາມຄືບຫນ້າຂອງມະເຮັງໄດ້ຖືກພົບເຫັນຢູ່ໃນການກວດຄືນໃຫມ່, ແລະຫຼັງຈາກນັ້ນການປິ່ນປົວ Tarceva ໄດ້ຖືກຢຸດເຊົາແລະການປິ່ນປົວ Libita ໄດ້ເລີ່ມຕົ້ນສໍາລັບ 16 ຮອບວຽນ. ໃນເວລາດຽວກັນ, ກະດູກສັນຫຼັງ metastasis ໄດ້ຖືກພົບເຫັນແລະ 4 ຮອບວຽນຂອງ Zetai ໄດ້ຖືກປະຕິບັດ.

2. ຄັ້ງທໍາອິດທີ່ຈະເຂົ້າຮ່ວມໃນການທົດລອງທາງດ້ານການຊ່ວຍ, ສະພາບແມ່ນຢູ່ພາຍໃຕ້ການຄວບຄຸມ.

In July 2010, Mr. Lu reexamined a large area of ​​brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.

3. ໃນການທົດລອງທາງດ້ານການຊ່ວຍຄັ້ງທີສອງ, tumor ຫາຍໄປຢ່າງຈະແຈ້ງ.

On August 6, 2012, Mr. Lu participated in the AP26113 drug ການທົດລອງທາງດ້ານການຊ່ວຍ at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the ເນື້ອງອກໃນສະອງ decreased and became large.

4. ຄົ້ນພົບການກາຍພັນຂອງ gene ທີ່ຫາຍາກ ແລະຫວັງວ່າຈະໄດ້ເຂົ້າຮ່ວມໃນການທົດລອງທາງຄລີນິກໃໝ່

ການກວດຄືນໃຫມ່ໃນເດືອນກໍລະກົດ 2014, PET ຂອງຮ່າງກາຍທັງຫມົດສະແດງໃຫ້ເຫັນວ່າ: ບາດແຜຂອງສະຫມອງແມ່ນມີຄວາມຫມັ້ນຄົງໂດຍພື້ນຖານ, ແລະຫນ້າເອິກມີຄວາມກ້າວຫນ້າຢ່າງຈະແຈ້ງ. ໃນວັນທີ 12 ພຶດສະພາ 2014, ກວດພົບເຊື້ອສາຍພັນ lymph ທີ່ສົງໃສວ່າຕ້ານເຊື້ອ AP26113 (3 ເຊນ, ໃຫຍ່ສຸດ 1.1 ຊມ) ໄດ້ດໍາເນີນຢູ່ໂຮງໝໍທົ່ວໄປຂອງລັດ Massachusetts ແລະສືບຕໍ່ກິນ AP26113.

In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.

On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.